Puma Biotechnology, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+9.73%
vs ±45.0% implied · ×0.22
shaded = implied · ▲▼ = realized
Linked news
Puma Biotechnology has 2 disclosed suppliers and 16 disclosed customers in SEC filings.
SentenceUnder the Pfizer Agreement, Pfizer was obligated to transfer to us certain information, records, regulatory filings, materials and inventory controlled by Pfizer and relating to or useful for developing these compounds and to continue to conduct certain ongoing clinical studies until a certain time.
SentenceThe specialty pharmacy network sells directly to patients and consists of Accredo, CVS, ONCO 360, Optum and Biologics.
PBYI 10-Kaccession 0001437749-26-005891
SentenceOur specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.
PBYI 10-Kaccession 0001437749-26-005891
SentenceOur specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.
PBYI 10-Kaccession 0001437749-26-005891
SentenceDuring the second quarter of 2020, we entered into a sub-license agreement (the "Bixink Agreement") with Bixink Therapeutics Co., Ltd. ("Bixink").
PBYI 10-Kaccession 0001437749-26-005891
SentenceOn February 24, 2021, we resolved a dispute with our former partner CANbridge Biomed Limited and terminated our sub-license agreement.
PBYI 10-Kaccession 0001437749-26-005891
SentenceOur specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.
PBYI 10-Kaccession 0001437749-26-005891
SentenceUnder the terms of the Knight Agreement, we will be solely responsible for the manufacturing and supply of the licensed products to Knight, but under limited circumstances Knight may obtain the right to manufacture the licensed products under the supply agreement.
PBYI 10-Kaccession 0001437749-26-005891
SentenceDuring the first quarter of 2018, we entered into a sub-license agreement (the "Medison Agreement"), with Medison Pharma Ltd. ("Medison").
PBYI 10-Kaccession 0001437749-26-005891
SentenceThe specialty pharmacy network sells directly to patients and consists of Accredo, CVS, ONCO 360, Optum and Biologics.
PBYI 10-Kaccession 0001437749-26-005891
SentenceThe specialty pharmacy network sells directly to patients and consists of Accredo, CVS, ONCO 360, Optum and Biologics.
PBYI 10-Kaccession 0001437749-26-005891
SentenceUnder the terms of the Pierre Fabre Agreement, as amended, we are obligated to supply Pierre Fabre with the licensed products in accordance with the related supply agreement.
PBYI 10-Kaccession 0001437749-26-005891
SentenceOn March 30, 2018, we entered into a sub-license agreement (the "Pint Agreement"), with Pint Pharma International SA ("Pint").
PBYI 10-Kaccession 0001437749-26-005891
SentenceWithin the STA Territory, STA will be generally responsible for regulatory and commercialization activities, and we will be solely responsible for the manufacturing and supply of the licensed product under a supply agreement entered into between the parties.
PBYI 10-Kaccession 0001437749-26-005891
Puma Biotechnology, Inc.
10.42
−0.12 · −1.09%
post 10.43 0.00%
Expected move
Inputs8Q avg ±12.8%·×1.00·fair
straddle ±15.7%
spot 10.44exp Nov 20ATM strike 10ATM straddle 1.92IV 97%